派罗欣对ALT低水平的慢性乙型肝炎疗效观察  

The therapeutic effects of pegasys in chronic hepatitis B patients with low-level ALT

作　　者：钱云松[1] 李凌[2] 

机构地区：[1]宁波市第二医院消化四科,315010 [2]宁波市第二医院消化三科,315010

出　　处：《中华实验和临床病毒学杂志》2013年第3期196-198,共3页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的 了解派罗欣对ALT低水平但肝组织炎症活动度≥G2的慢性乙型肝炎患者的疗效.方法 随机选择52例ALT低水平（ALT ＜2×ULN）但肝组织炎症活动度≥G2的慢性乙型肝炎患者为观察组,55例ALT＞2 ×ULN的慢性乙型肝炎患者为对照组,分别接受派罗欣治疗48周,并对两组患者的疗效进行比较.计量资料采用t检验,计数资料采用x2检验.结果 观察组HBV DNA下降值（log10拷贝/ml）在治疗不同时期均低于对照组（均P＜0.05）.治疗结束时观察组HBV DNA转阴率、HBeAg血清转换率及HBsAg转阴率分别为51.9％、48.8％和1.9％；对照组分别为67.3％、66.7％和7.3％；两组比较差异均有统计学意义（均P＜0.05）.两组患者的ALT复常率分别为75％和76.4％ （P ＞0.05）.结论 派罗欣对ALT低水平但肝组织炎症活动度≥G2的慢性乙型肝炎患者有一定疗效,但仍逊于ALT＞2×ULN者.Objective To observe the therapeutic effects of Pegasys （pegylated interferon α-2a）in chronic hepatitis B （CHB） patients with low-level alanine transarninase （ALT） ＜ 2 × upper limit of normal （ULN）.Methods One hundred and seven CHB patients were randomized enrolled including 52 with ALT ＜ 2 × ULN and liver tissues inflammation activity≥ G2 as observational group and 55 with ALT ＞ 2 × ULN as control group.All the enrolled patients received pegasys treatment for 48 weeks and the responses between two groups were compared.Measurement data were analyzed using t test and numeration data were analyzed using chi square test.Results The reductions of HBV DNA in observational group at different time points were all less than control group （all P ＜ 0.05）.At the end of treatment,the HBV DNA negative rate,HBeAg seroconversion rate and HBsAg loss rate in the observational group were 51.9％,48.8％ and 1.9％,respectively,which were all lower than control group （67.3％,66.7％ and 7.3％,respectivley） （all P ＜ 0.05）.The ALT normalization rates of two groups were 75％ and 76.4％ （P ＞ 0.05）.Conclusion Pegasys is efficient for CHB patients with ALT ＜ 2 × ULN and liver tissues inflammation activity ≥ G2,while it is still inferior to those with ALT ＞ 2 × ULN.

关 键 词：派罗欣 肝炎 乙型 慢性 丙氨酸转氨酶 

分 类 号：R512.62[医药卫生—内科学]